Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professor Andrew Pollard, named as one of three 2019 Rosén von Rosenstein laureates.

The Rosén von Rosenstein Medal is awarded by the University of Uppsala, Sweden

Andy Pollard receives the Rosen von Rosenstein Medal The Rosén von Rosenstein Medal, awarded by the Swedish Paediatric Society and the Swedish Society of Medicine every five years since 1964, is recognised as the most prestigious prize within paediatrics.

Andrew Pollard is Professor of Paediatric Infection and Immunity at the University of Oxford, Director of the Oxford Vaccine Group, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College. His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal; he also leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi, and co-leads typhoid vaccine impact studies at these sites. He has supervised 37 PhD students and his publications includes over 500 manuscripts and books on various topics in paediatrics and infectious diseases. He chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s SAGE. He was elected to the Academy of Medical Sciences in 2016 and is an NIHR Senior Investigator. His recent recognitions include the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 for his contribution to the specialty, and the ESPID Distinguished Award for Education & Communication in 2015.

Professor Pollard received the medal in a ceremony on 27 September and delivered a lecture in the Children's Hospital at Uppsala.

About the award

The prize commemorates Nils Rosén von Rosenstein (1706-1773), a Swedish physician and the founder of modern paediatrics. Following studies at the universities of Lund and Uppsala, Rosén von Rosenstein travelled to several European countries and obtained a medical degree in Haarderwijk in 1730. He subsequently returned to take up a lectureship in Uppsala, where he was Carl Linnaeus’ contemporary. In 1743 he was appointed royal physician. In 1764, Rosén von Rosenstein published “The diseases of children, and their remedies”, considered to be the first modern textbook on the subject.

Similar stories

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, which has been developed by the Draper Lab in the Department of Paediatrics, and is based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.

World's first Phase II Nipah virus vaccine trial launch

The University of Oxford has launched the world’s first Phase II clinical trial of a Nipah virus vaccine candidate.